Syngene International Limited

NSEI:SYNGENE Stock Report

Market Cap: ₹338.7b

Syngene International Past Earnings Performance

Past criteria checks 2/6

Syngene International has been growing earnings at an average annual rate of 6.2%, while the Life Sciences industry saw earnings growing at 25.3% annually. Revenues have been growing at an average rate of 14.2% per year. Syngene International's return on equity is 11%, and it has net margins of 14%.

Key information

6.2%

Earnings growth rate

5.9%

EPS growth rate

Life Sciences Industry Growth11.2%
Revenue growth rate14.2%
Return on equity11.0%
Net Margin14.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems

Oct 31
Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems

Recent updates

Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems

Oct 31
Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems

Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing

Jul 16
Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Mar 28
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?

Feb 14
Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?

Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)

Jan 19
Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)

Is Syngene International (NSE:SYNGENE) A Risky Investment?

Nov 19
Is Syngene International (NSE:SYNGENE) A Risky Investment?

Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?

Nov 01
Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?

Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly

Aug 07
Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Apr 28
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Apr 06
Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Jan 04
Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Dec 08
Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Aug 28
Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

Aug 10
Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

May 10
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

Revenue & Expenses Breakdown

How Syngene International makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:SYNGENE Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2434,5114,8199,8080
30 Jun 2434,7024,9239,5480
31 Mar 2434,8865,1009,4030
31 Dec 2335,6615,0029,5160
30 Sep 2334,9854,9849,4150
30 Jun 2333,5654,8399,2320
31 Mar 2331,9294,6448,9390
31 Dec 2229,5664,3348,1000
30 Sep 2228,1214,2777,8800
30 Jun 2226,5423,9247,6540
31 Mar 2226,0423,9587,5040
31 Dec 2125,0474,0867,4610
30 Sep 2124,4784,0687,3330
30 Jun 2123,5724,2427,0990
31 Mar 2121,8434,0496,7920
31 Dec 2021,3303,6456,6190
30 Sep 2020,6763,5416,3820
30 Jun 2020,1263,9816,0880
31 Mar 2020,1194,1216,0060
31 Dec 1919,3853,9205,7800
30 Sep 1918,8653,8725,4460
30 Jun 1918,4053,3745,2770
31 Mar 1918,2563,3165,0320
31 Dec 1817,0083,1604,7330
30 Sep 1816,2143,1104,5020
30 Jun 1815,3803,0964,2900
31 Mar 1814,2313,0544,0730
31 Dec 1713,0532,9933,7220
30 Sep 1712,4972,9173,5650
30 Jun 1712,1752,8953,3950
31 Mar 1712,0092,8733,2740
31 Dec 1612,4112,6823,2200
30 Sep 1611,8942,6063,0210
30 Jun 1611,4792,3442,8260
31 Mar 1611,0702,4082,6770
31 Dec 1510,2352,1032,79866
30 Sep 159,7131,9642,70966
30 Jun 159,0171,8432,2730
31 Mar 158,5991,7502,1860
31 Mar 146,9951,3391,9940

Quality Earnings: SYNGENE has high quality earnings.

Growing Profit Margin: SYNGENE's current net profit margins (14%) are lower than last year (14.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SYNGENE's earnings have grown by 6.2% per year over the past 5 years.

Accelerating Growth: SYNGENE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SYNGENE had negative earnings growth (-3.3%) over the past year, making it difficult to compare to the Life Sciences industry average (38.1%).

Return on Equity

High ROE: SYNGENE's Return on Equity (11%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:02
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Syngene International Limited is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAsian Markets Securities Private Limited
Harith AhamedAvendus Spark
Kunal RanderiaAxis Capital Limited